शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

BSEISHITA DRUGS & INDUSTRIES LTD.· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 3 Nov, 2026 · 17:27 IST

Q2 FY27 standalone results: half-year profit after tax Rs 39.10 lakh, no review concerns

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction

Awaiting price reaction for this filing.

AI summary

Standalone results for the quarter ended 30 September 2026 were approved; the extract lacks revenue and profit after tax comparatives. Standalone half year: profit after tax was Rs 39.10 lakh, profit before tax Rs 51.40 lakh and operating cash flow Rs 54.14 lakh. Auditors found no material misstatement; prior-quarter figures were regrouped or reclassified. Capital work in progress rose to Rs 285.63 lakh after about Rs 488 lakh of upgrade spending.

Likely market impact

Positive half-year cash flow and low debt support stability; the upgrade may aid compliance but needs continued capital spending.

By the numbersStandalone · Q2 FY27 vs Q2 FY26
Q2 FY27Q2 FY26Change
Revenue₹3.03 Cr₹3.07 Cr−1.1%
Operating profit₹0.06 Cr₹0.15 Cr−64.2%
Profit after tax₹0.16 Cr₹0.14 Cr+12.2%
EBITDA margin5.4%6.0%−0.7 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.